Statin use and risk of hepatocellular carcinoma
Resource
Eur. J. Epidemiol., 28(6), 485-492
Journal
European Journal of Epidemiology
Pages
485-492
Date Issued
2013
Date
2013
Author(s)
Lai, Shih-Wei
Liao, Kuan-Fu
Lai, Hsueh-Chou
Muo, Chih-Hsin
Sung, Fung-Chang
Chen, Pei-Chun
Abstract
The objective of this study was to explore the association between statins use and risk of developing hepatocellular carcinoma (HCC). We used the research database of the Taiwan National Health Insurance program to conduct a population-based case-control study. Cases were 3,480 patients with newly diagnosed HCC identified during 2000 and 2009. Controls were 13,920 subjects without HCC and frequency matched for age, sex and duration of observational period of cases (i.e., the duration between year of being enrolled in the insurance program and index year of cases). Six commercially available statins, including simvastatin, lovastatin, fluvastatin, atorvastatin, pravastatin, and rosuvastatin, were analyzed. The adjusted odds ratio [OR] of HCC was 0.72 [95 % (CI) 0.59-0.88] for the group with stains use, when compared to the group with non-use of statins. In sub-analysis, simvastatin (OR 0.69, 95 % CI 0.50-0.94), lovastatin (OR 0.52, 95 % CI 0.36-0.76) and atorvastatin (OR 0.70, 95 % CI 0.53-0.93) were associated with significant reduction in odds of HCC. Statins use correlates with 28 % decreased risk of HCC. Individual statins, including simvastatin, lovastatin and atorvastatin, are associated with reduced risk of HCC.
Subjects
Hepatocellular carcinoma
Statin
SDGs
Other Subjects
atorvastatin; fluindostatin; mevinolin; pravastatin; rosuvastatin; simvastatin; adult; age; article; cancer risk; chronic liver disease; controlled study; disease association; dose response; drug effect; drug megadose; drug safety; drug use; female; human; liver cell carcinoma; low drug dose; major clinical study; male; population based case control study; risk assessment; risk reduction; sex difference; treatment duration; Adult; Aged; Carcinoma, Hepatocellular; Case-Control Studies; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insurance, Health; Liver Neoplasms; Logistic Models; Male; Medical Record Linkage; Middle Aged; Odds Ratio; Population Surveillance; Proportional Hazards Models; Registries; Risk; Taiwan
File(s)![Thumbnail Image]()
Loading...
Name
index.html
Size
23.17 KB
Format
HTML
Checksum
(MD5):cc440be1e7a6d240b9fab7f33aa84a91